NIH’s National Center for Advancing Translational Science (NCATS) announced last week that it will partner with Lilly Research Laboratories, a division of Eli Lilly and Co., to screen the NCATS Pharmaceutical Collection using a drug discovery assay panel developed by Lilly.
The collection includes 3800 samples of approved and investigational drugs, coupled with a publicly available database of biological profile data. The goal of this “precompetitive collaboration” is to uncover new clinical targets for existing drugs and make that information available to companies and investigators interested in pursuing further studies.
